OSE Immunotherapeutics Unveils 2026-2028 Strategic Plan With Four Value-Creating Opportunities

OSE Immunotherapeutics unveiled a three-year plan to accelerate late-stage programs while maintaining financial discipline, concentrating resources on the pivotal Phase 3 ARTEMIA trial of Tedopi and on advancing Lusvertikimab through Phase 2 into selected rare or specialty indications. Tedopi's futility analysis is expected in Q3 2026 with a full readout in Q1 2028, and the company is pivoting its ulcerative colitis program to a subcutaneous formulation after Phase 2 IV data identified a biomarker predictive of strong response in roughly 25% of patients and suggesting up to ~30% could achieve remission; Lusvertikimab IV will be moved into one or two precision-medicine indications to be disclosed in early 2026 while combination and preclinical work continues at limited cost. OSE reports financial visibility into early Q4 2026 backed by potential milestone payments including EUR 17.5 million from Boehringer Ingelheim, and its shares traded at €4.73 (down 2.87%) on the Frankfurt exchange.

Analysis

OSE Immunotherapeutics has announced a three-year strategic plan prioritizing late-stage assets while emphasising financial discipline; the company confirmed progression of the pivotal Phase 3 ARTEMIA trial of Tedopi in non-small cell lung cancer with a futility analysis due in Q3 2026 and a full readout expected in Q1 2028. Tedopi remains supported by lower-cost investigator-led Phase 2 studies that could provide additional proof-of-concept data ahead of the Phase 3 milestones.

Lusvertikimab, an anti–IL‑7R monoclonal antibody in Phase 2, is being advanced into one or two rare or specialty IV indications using a precision‑medicine approach, with indication disclosure planned for early 2026; the company is concurrently pivoting the ulcerative colitis program to a subcutaneous formulation after the IV CoTikiS Phase 2 showed a biomarker predictive of strong response in ~25% of patients and signal potential for remission in up to ~30%. OSE also intends to explore combinations and progress preclinical assets at limited cost to preserve scientific leadership.

Corporate liquidity is visible into early Q4 2026, supported by potential milestone payments including EUR 17.5 million tied to Boehringer Ingelheim, while management plans to concentrate resources on near-term catalysts and ready assets for partnerships once Phase 3‑ready. The market reacted modestly negative intraday with shares at €4.73, down 2.87%, reflecting the cautious, mildly positive sentiment and the binary nature of upcoming clinical and milestone events.

Key Decisions for Investors

• Monitor the receipt and timing of the EUR 17.5 million Boehringer milestone and other near-term cash events as primary de‑risking triggers for the balance sheet
• Maintain a cautious, event‑driven exposure sized for binary clinical risk — consider a small speculative position to capture upside from the Q3 2026 futility check and the Q1 2028 readout for Tedopi, while limiting size to risk tolerance
• Watch Lusvertikimab biomarker validation and the early‑2026 disclosure of target indications closely; increase conviction only if biomarker‑defined populations and efficacy signals are confirmed
• Implement downside protection (stop losses or hedges) given limited runway to early Q4 2026 and potential for further share volatility, and reassess if management secures additional financing or partnerships